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ABSTRACT 
Background: Somatostatin receptors (SSTRs) occur in cancer tissue, and 99mTc-depreotide is a 
labelled somatostatin receptor analogue, binding to SSTRs subtype 2, 3, and 5. 
 
Purpose: The general aim of the present thesis was to study somatostatin receptor scintigraphy 
(SSTRS) with 99mTc-depreotide in the diagnosis and characterization of cancers in the lung and 
oesophagus. 
 
Study I evaluated the diagnostic value of the SSTRS with 99mTc-depreotide in 99 patients with 
suspected lung cancer. The sensitivity to detect malignancy was 94%, and to detect lung cancer 
98%. The specificity was calculated on two sets of data. When all cases are used, the specificity 
was 52%. If the 12 pneumonias are excluded, the specificity was 77%. 
Study II was performed on 19 patients with histologically proven non-small-cell lung cancer 
(NSCLC), where the expression of SSTR subtype 2 was looked for and found by 
immunochemical methods. The quantitative evaluation of 99mTc-depreotide was performed 
using region-of-interest analysis and includes tumour counts/cm3, background counts/cm3, and 
the ratio between tumour and background counts. SSTR subtype 2 expression was positively 
correlated to the degree of the tumour’s differentiation (p < 0.05). 99mTc-depreotide uptake in 
tumour cells did not correlate with tumour grade or SSTR subtype 2, MIB-1, or p53 expression. 
Study III showed the feasibility of imaging oesophageal carcinoma with SSTRS with 99mTc-
depreotide and optimal time intervals for imaging. None of the 13 cancer-free Barrett’s 
oesophagus patients in this study showed an increased 99mTc-depreotide uptake. 
Study IV investigated the expression of SSTRs of subtype 2A, 2B, 3, and 5 in 28 patients with 
suspected oesophageal cancer, where expression was detected in small amount in 
adenocarcinoma and was absent in squamous cell carcinoma. There was no correlation between 
the 99mTc-depreotide uptake and the amount of SSTRs, and no correlation between the amount 
of SSTRs and the differentiation grade of the tumour. 
 
Conclusion: SSTRS with the labeled somatostatin receptor analogue 99mTc-depreotide has a 
very high sensitivity for detecting lung cancer. A negative scintigraphy strongly suggests a 
benign lesion, and the method is useful in decision making with respect to surgery. 
 
There is an expression of SSTRS subtype 2 in NSCLC with a positive correlation between 
tumour differentiation and presence of SSTR subtype 2. There is no correlation between  
99mTc-depreotide uptake compared to tumour differentiation, presence of SSTR subtype 2, p53, 
or MIB-1, and SSTRS cannot be used as a prognostic factor in patients with lung cancer. 
 
SSTRS with 99mTc-depreotide of oesophageal cancer is feasible, but not suitable, for either 
screening or primary diagnosis, because of the method’s modest sensitivity. However, this 
method has a high specificity. The majority of patients with adenocancer of the oesophagus 
have a low amount of SSTRs, while most of the patients with squamous cell cancer do not have 
any of SSTRs. 
 
Keywords: Lung cancer; oesophageal cancer; Barrett’s oesophagus; 99mTc-depreotide 
scintigraphy; prognostic factor; somatostatin receptor expression; immunohisto-
chemistry. 
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LIST OF ABBREVIATIONS 
 
Ac Adenocarcinoma 
CT Computed Tomography 
64Cu Radioactive nuclide of Copper 
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DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
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DTPA Diethylenetriaminopentaacetic acid 
EUS Endoscopic ultrasound 
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68Ga-DOTA-NOC Radiolabelled DOTA -NI,NII,NIII,NIIII-tetraacetic 
acid-1-Nal3-octreotide 
68Ga-DOTA-TATE 68Ga-DOTA-D-Phe1-Tyr3-Thr8-octreotide or  
68Ga-DOTA-D-Phe1-Tyr3-octreotate 
68Ga-DOTA-TOC Radiolabelled DOTA-Phe1-Tyr3-octreotide 
GH Growth hormone 
HOSEM OSEM in Hermes 
HRCT High Resolution Computed Tomography 
111In Radioactive nuclide of Indium 
Ki-67 An antigen and a marker for cell proliferation.  
177Lu Radioactive nuclide of Lutetium  
MAPK Mitogen-activated protein kinase 
MBq Milli Becquerel Used in the International System of Units (SI),  
the becquerel (Bq) is the unit of radioactivity.  
One Bq is 1 disintegration per second (dps). 
MIB-1 Molecular Immunology Borstel, the antibody against 
Ki-67 
MRT Magnetic Resonance tomography 
NET Neuroendocrine tumour 
  
NP Neuropeptide 
NSCLC Non-small-cell lung cancer  
OSEM Ordered subset expectation maximization  
P53 A nuclear phosphoprotein whose function is classified 
as a tumour suppressor gene 
PRRT Peptide receptor radionuclide therapy 
ROI Region of interest 
SCLC Small-cell lung cancer 
SPECT Single Photon Emission Computed Tomography 
SPN Solitary pulmonary nodule 
SqCC Squamous cell cancer 
SST Somatostatin 
SSTR Somatostatin receptor 
SSTR1, SSTR2A, SSTR2B, 
SSTR3 and SSTR5 
Somatostatin receptors of 5 different types: 1, 2A, 2B,  
3, and 5 
SUV Standardized uptake value 
TNM staging Staging of tumour spread. T is local spread of the 
tumour mass, N is spread to lymph nodes, and M is 
distant metastases 
US Ultrasound 
VOI Volume of interest 
90Y Radioactive nuclide of Yttrium  
 
   1 
1 INTRODUCTION 
1.1 BACKGROUND 
Cancer arises through a variety of mechanisms resulting in uncontrolled cell division, 
which play an important role in tumour development and spread. By defining key 
pathways in those proliferative processes, the ambition has been to make it possible 
to target specific metabolic pathways’ or receptors’ steps, allowing tumour detection 
and collection of prognostic information relevant to diagnosis as well as treatment. 
Selective receptor-targeting radiopeptides have emerged as an important class of 
radiopharmaceuticals for molecular imaging and therapy of tumours that overexpress 
peptide receptors on the cell membrane. After such peptides labelled with gamma-
emitting radionuclides bind to their receptors, they allow clinicians to visualize 
receptor-expressing tumours non-invasively. Peptides labelled with beta-particle 
emitters could also eradicate receptor-expressing tumours. For evaluation of tumour 
receptor expression and to increase the value of cancer targeting using radiopeptides, 
researchers have introduced and evaluated different radiolabelled analogues of 
peptide families, such as somatostatin, cholecystokinin, gastrin, bombesin, substance 
P, vasoactive intestinal peptide, and neuropeptide analogues. The somatostatin 
receptors (SSTRs), which are overexpressed in a majority of neuroendocrine tumours, 
represent the first and best example of targets for radiopeptide-based imaging and 
radionuclide therapy. 
 
Somatostatin (SST) is a polypeptid which is primarily produced in the hypothalamus 
and pancreas and normally occurs in the nervous tissue, hypothalamo-pituitary 
system, and peripheral tissue like that of the gastro-intestinal canal, endocrine 
pancreas, kidneys, spleen, prostatic gland, and thyroid gland (1, 2). Two molecular 
forms of somatostatin, SST-14 and SST-28, have been identified (3, 4). In mammals 
these two peptides are encoded by a single gene that yields a peptide 
(preprosomatostatin) that is subsequently cleaved to generate SST-14 or SST-28. It is 
a modulator of neurotransmission, cell secretion, and cell proliferation (5). SST is 
also considered to be a neurotransmitter, a neurohormone, or a local hormone acting 
via autocrine or paracrine mechanisms (5). It is also an inhibitor of secretion of 
various hormones like neuroendocrine hormones, growth hormone, glucagone, 
insulin, and gastrin (6). Somatostatin and somatostatin analogues inhibit tumour 
growth (7, 8). SST has an inhibitory action through the mitogen-activated protein 
kinase (MAPK) pathways. This could be one effect of somatostatin signalling (9). 
MAPK activation is important for cell proliferation (10); therefore inhibition of 
MAPK is likely to contribute to the antiproliferative effect of SST. The role of SST in 
stimulating apoptotic mechanisms in SST2- or SST3-expressing cells (11, 12) is 
another notable antiproliferative mechanism. 
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SST could have two different actions against tumours, partly by direct mechanism 
such as the above mentioned, or by indirect mechanism, for example, by octreotide-
induced inhibition of pituitary growth hormone (GH) secretion, which reduces growth 
on GH-dependent tumours (13). Another indirect mechanism action against tumours 
could be SST analogues acting by inhibition of angiogenesis (14, 15). 
 
Somatostatin receptors (SSTRs) The SST acts by binding on protein-coupled 
receptors called somatostatin receptors (SSTRs). There are 6 subtypes of SSTRs: 
SSTR1, SSTR2A, SSTR2B, SSTR3, SSTR4, and SSTR5 (2, 5, 16). These 6 subtypes 
are encoded by different genes, except SSTR2A (5). SSTRs occur in some tumours in 
much higher concentrations than in normal tissue. High concentrations of SSTRs 
have been found, for example, in neuroendocrine tumours (17–19), gastroentero-
pancreatic tumours (20, 21), phaechromocytomas (22, 23) and to a lesser extent 
small-cell lung cancers (24). Other tumours that express SSTRs are lymphomas (25), 
renal cell cancers (26), mesenchymal tumours (27), gastric tumours (28, 29), and 
hepatocellular tumours (30, 31). 
 
There are 3 main ways to identify SSTRs in normal tissues and in cancer cells. One is 
by autoradiography with receptor binding with radioactive labelled SST analogues, 
different substances binding to the different somatostatin receptors SSTR1, SSTR2, 
SSTR3, SSTR4, and SSTR5 (32, 33). The second method is with receptor mRNA; 
human tumours often express multiple SSTRs subtype mRNAs, as reported first in 
pituitary adenomas (34, 35, 32) and gastroenteropancreatic tumours (32). The third 
method is receptor immunohistochemistry. This method has the advantage of a high 
cellular resolution. But the results depend on the quality, selectivity, and specificity of 
the applied antibodies. Even highly specific antibodies SSTR2A such as R2-88 can 
weakly cross-react with unrelated proteins (36). 
 
1.2 SOMATOSTATIN RECEPTOR SCINTIGRAPHY (SSTRS)  
The first radiolabelled SST analogue used for diagnostic purpose was an iodinated 
125I- or 123I-Tyr3-octreotide (36). By linking chelators DTPA (diethylenetriamino-
pentaacetic acid) or DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid), which are indispensable molecules, to accept certain types of metallic radio-
isotopes (37), this also improved the biodistribution profile with a shift from a 
gastrointestinal excretion pathway to a predominant renal excretion (36).  
 
Octreoscan (111In-DTPA-D-Phe1octreotide) is the most widely used radiopharma-
ceutical for SSTRS. The best and most consistent results are found in tumours 
expressing a high density of SSTRs, namely the majority of neuroendocrine tumours, 
but also meningiomas and medulloblastomas (38, 39). Successful scintigraphy has 
also been reported for other tumour types, with lower or non homogeneous SSTR 
density, such as breast cancer, lymphomas, or renal cell carcinomas (40–44). 
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Depreotide (P829) is an SST analogue, which is a cyclic synthetic peptide that can 
be labelled with Technetium-99m, yielding 99mTc-depreotide. It is known under the 
commercial names NeoTect (USA) and NeoSpect (Europe) (45, 36). Depreotide 
binds to SSTR2A, SSTR2B, SSTR3, and SSTR5, while Octreoscan binds to SSTR1, 
SSTR3, and SSTR5. There are some advantages 99mTc-depreotide  scintigraphy over 
111In-Octreoscan: besides the fact that 99mTc-depreotide has high affinity to the 
SSTR2 receptor, which occurs in many tumours,  99mTc-depreotide has a shorter half-
life, allowing the patient to be imaged the same day, and a lower radiation dose 
compared to 111In-Octreoscan. The disadvantage of imaging with 99mTc-depreotide is 
the relatively high abdominal background and the impossibility of performing 
delayed imaging due to the short half-life of the tracer, thus making it less suitable for 
the detection of abdominal tumours. 99mTc-depreotide was extensively applied to 
imaging of solitary pulmonary noduli (46–48). 
 
Tracers for Positron Emission Tomography (PET) The PET camera allows a 
higher spatial resolution compared to the gamma camera, which makes it possible to 
image tumours with an even higher accuracy. In fact, PET imaging of neuroendocrine 
tumours (NET) is a rapidly evolving field, closely connected to the development of 
novel radiopharmaceuticals. NET can be easily visualized on PET scans using an 
array of receptor-based tracers. More recently the labelling of SST analogues with 
68Ga, 64Cu, or 18F resulted in the development of specific PET tracers (DOTA-
peptides) that are currently employed in clinical trials in NET patients (68Ga-DOTA-
TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE) with very promising results, reported 
to be superior to other imaging modalities (computed tomography (CT), magnetic 
resonance tomography (MRT),or SSTRS (49–55). 
 
1.3 THERAPEUTIC USE OF SST  
Peptide receptor radionuclide therapy (PRRT) with radiolabelled SST analogues is a 
promising treatment option for patients with inoperable or metastatic neuroendocrine 
tumours. Symptomatic improvement may occur with all of the various 111In, 90Y, or 
177Lu–labelled SST analogues that have been used. Since tumour size reduction was 
seldom achieved with 111Indium-labelled SST analogues, radiolabelled SST 
analogues with beta-emitting isotopes like 90Y and 177Lu were developed. Reported 
anti-tumour effects of [90Y-DOTA(0),Tyr(3)]octreotide vary considerably between 
various studies: Tumour regression of 50% or more was achieved in 9 to 33% (mean 
22%) of patients. With [177Lu-DOTA(0),Tyr(3)]octreotate treatments, tumour 
regression of 50% or more was achieved in 28% of patients and tumour regression of 
25 to 50% in 19% of patients; stable disease was demonstrated in 35% and 
progressive disease in 18%. Predictive factors for tumour remission were high tumour 
uptake on SSTRS and limited amount of liver metastases. The side effects of PRRT 
are few and mostly mild, certainly when using renal protective agents. Serious side 
effects like myelodysplastic syndrome or renal failure are rare. The median duration 
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of the therapy response for [90Y-DOTA(0),Tyr(3)]octreotide and [177 Lu-DOTA(0), 
Tyr(3)]octreotate is 30 months and more than 36 months, respectively. Lastly, quality 
of life improves significantly after treatment with [177Lu-DOTA(0),Tyr(3)]octreotate.  
These data compare favourably with the limited number of alternative treatment 
approaches, like chemotherapy (36, 56–64). 
 
Another possibility for tumour treatment could be the use of unlabelled somatostatin 
coupled to cytotoxic agents. One of the most efficient compounds is AN-238, a potent 
cytotoxic radical 2-pyrrolinodoxorubicin linked to the somatostatin octapeptide RC-
121, (36, 65). However AN-238 has not yet been tested in clinical trials (36). 
 
Apart from patient selection for radionuclide therapy, other imaging applications of 
SSTRS include localization of primary tumours, detection of metastatic disease 
(staging/restaging), dosimetry (prediction of response and radiotoxicity), monitoring 
effects of surgery, radio(nuclide)therapy or chemotherapy, and detection of 
progression of disease or relapse (follow-up). 
 
 
1.4 LUNG CANCER 
Lung cancer is the second most common cancer in both men and women in the 
Nordic countries combined, with rates only superseded by prostate and breast cancer, 
respectively, while it is the most common cause of cancer death. The incidence of 
lung cancer per year in Sweden has increased since 1958, and during 1990–1994 was 
slightly over 2800 (66). While the incidence rates in males have been decreasing in 
Sweden since 1980, the incidence rates in females have increased. The mortality 
trends closely follow those of incidence, reflecting the very unfavourable survival of 
the patients in general (67). 
 
Histopathologically, there are two main groups of lung tumours: small-cell lung 
cancer (SCLC) and non-small-cell lung cancer (NSCLC). There are several 
subgroups of tumours among the NSCLC, with adenocarcinoma (Ac) the most 
common, followed by squamous cell cancer (SqCLC). Other forms of cancer in the 
lungs are bronchioloalveolar carcinoma and adenosquamous lung cancer, 
mucoepidermoid, and large-cell lung cancer. 
 
The 5-year survival rates are closely related to the disease stage at the time of 
diagnosis, which is illustrated in Table 1 (68). 
 
 
 
 
 
   5 
Table 1. Comparison of overall survival between TNM classifications by using the sixth edition 
of TNM classifications. 
 
Sixth edition 
TNM 
Deaths/no. Median survival 
(mo) 
5-Year survival 
(%) 
P-value 
T1 120/830 53 78.7 – 
T2 166/525 46 60.9 <.0001 
T3 58/98 35 34.5 <.0001 
T4 38/79 33 36.9 .8373 
N0 192/1148 52 77.0 – 
N1 60/161 45 54.2 <.0001 
N2 122/212 32 28.4 <.0001 
N3 8/11 11 0.0 .0002 
M0 360/1497 50 68.2 – 
M1 22/35 24 27.1 <.0001 
Total 382/1532 49 67.3 – 
P-value: Significance value from log-rank test of survival hazard functions relative to preceding row. 
 
Improved radiologic imaging techniques have affected the clinical staging of lung 
tumours. Recent recommendations for revisions to the TNM classification and 
staging system for non-small-cell lung carcinoma attempt to incorporate these new 
data, with the intent of refining clinical groups to lead to more appropriate therapy for 
individual patients. Also, improvements in radiologic detection techniques have led to 
the discovery of smaller lesions, which may be successfully treated with less rigorous 
chemotherapeutic and surgical protocols. 
 
The radiological diagnostic procedures routinely applied in lung cancer diagnosis 
include plain X-ray of the lungs and computed tomography of the thorax and 
abdomen for diagnosing spread of the tumour. The most common manifestation of 
lung cancer is a solitary pulmonary nodule (SPN) smaller than 3 cm in diameter, 
which is usually found during CT, or a solitary pulmonary mass larger than 3 cm in 
diameter. Diagnostic evaluation of focal pulmonary lesions should be accurate and 
efficient to facilitate prompt resection of malignant tumours, when possible, but 
surgery should be avoided in cases of benign disease. 
 
The systematic literature review showed that dynamic CT with nodule enhancement 
yielded the promising sensitivity for identifying a malignant SPN (98 to 100%) with 
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less favourable and often poor specificity varying between 54 and 93%. In studies of 
CT-guided needle biopsy, non-diagnostic results were seen approximately 20% of the 
time, but sensitivity and specificity were excellent when biopsy yielded a specific 
benign or malignant result (69). 
 
MRT could be used in special situations to see the growth of the tumour to 
surrounding tissue, for example, overgrowth of Pancoast tumours to the spine with 
symptoms of nerve root compression or compression on the spinal cord. 
 
To investigate tumour spread, other diagnostic procedures could be used, such as 
ultrasonography of the abdomen or endoscopic examination of the oesophagus 
(oesophagoscopy) combined with endoscopic ultrasonography (EUS) and combined 
with needle biopsy and CT of the brain or bone scintigraphy. 
 
For staging purposes positron emission tomography with F18-Fluoro-deoxy-glucose 
(FDG-PET) is now a routine method (70–72). Imaging with FDG-PET is a sensitive 
method to detect pulmonary cancer, but as with CT, it has a limited specificity (71–
72). FDG-PET reflects the metabolic activity with glucose turnover and is not 
specific for the malignancies. Search for other, more tumour-specific imaging agents 
remains desirable. 
 
SSTRS with99mTc-depreotide  in patients with lung cancer 
A noninvasive functional imaging method based on the principle that malignant 
nodules have a higher level of somatostatin-avid receptors than benign nodules do 
was tested in several studies. 
 
99mTc-depreotide was extensively applied for imaging of solitary pulmonary noduli 
during last decade. This SST analogue is labelled with gamma-emitting 99mTc and 
thus could be easily imaged with a single-photon gamma camera, which is more 
widely available than PET/CT scanners. 
 
Single-site studies have reported promising results regarding diagnostic performance 
of 99mTc-depreotide (47, 73). And two large multicentre studies were conducted. In a 
United States multicentre study of 114 individuals, Blum et al. (46) reported that 
99mTc-depreotide scintigraphy correctly identified 85 of 88 lung cancers, resulting in 
96.6% sensitivity. Methods specificity, however, was lower (73.1%), with false-
positive uptake in granulomas and one hamartoma. 
 
In the European multicentre study of 118 patients (48) 99mTc-depreotide was positive 
in 65 of 73 patients with a malignant lesion and negative in 30 of 45 patients with a 
benign lesion, resulting in a sensitivity, specificity, and diagnostic accuracy of 89,67 
and 81%, respectively. 
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99mTc-depreotide  vs. FDG-PET in patients with lung cancer 
In the beginning of this century PET technology was available in only few large 
clinical centres in the United States and Europe, and it was of great importance to 
compare these two methods. The diagnostic performance between FDG-PET and 
99mTc-depreotide-SPECT in the European multicentre study appears comparable; and 
scintigraphy with 99mTc-depreotide is advantageous, since it can be performed with 
traditional nuclear medicine equipment (48). The results of examinations performed 
with 99mTc-depreotide suggest that this test has sensitivity and specificity similar to 
those of FDG-PET (72). 
 
In a study by Kahn et al. (71) 157 subjects with lung lesions were examined with both 
methods, and the sensitivities and specificities for detecting malignant disease of 
FDG-PET were 96% and 71%, and of 99mTc-depreotide were 94% and 51%, 
respectively. In the 139 subjects with available complete staging data, FDG-PET 
correctly staged 76 of 139 patients (55%), and 99mTc-depreotide correctly staged 63 of 
139 patients (45%). The authors concluded that the sensitivity for detection of lung 
cancer in the primary lesion is equally high for FDG-PET and 99mTc-depreotide, but 
the specificity is superior for FDG-PET. The staging accuracy of FDG-PET and 
99mTc-depreotide is similar, but when read with the chest CT, neither scintigraphic 
examination is sufficiently accurate to stage patients with non-small-cell lung cancer. 
Performing a meta-analysis to estimate the diagnostic accuracy of dynamic contrast 
enhanced CT and magnetic resonance imaging, FDG-PET, and technetium 99mTc-
depreotide single photon emission computed tomography (SPECT) for evaluation of 
solitary pulmonary nodules (SPNs), Croning et al. (74) found that all these non-
invasive methods are accurate in distinguishing malignant from benign SPNs, and 
differences among these tests are non-significant. 
 
The previous studies with 99mTc-depreotide in lung cancer patients from our group 
were in line with research published worldwide and showed promising results in the 
detection of primary lung cancer and regional lymph nodes (71–72, 75). However, the 
data on clinical application of this method are missing. 
 
Prognosis in patients with NSCLC 
The prognosis for patients with non-small-cell lung cancer depends on a number of 
factors, including the extent of disease, performance status, weight loss, and TNM 
staging. Unfortunately, these variables do not always provide a satisfactory 
explanation for differences in survival rates. Different biological markers may 
provide further explanations for differences in prognosis. Such biological markers 
could be p53 or Ki-67 with the corresponding antibody MIB-1. 
Prognostic biological markers: 
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P53 is a nuclear phosphoprotein whose function is classified as a tumour suppressor 
gene (76–83). Mutations in the p53 gene are currently regarded as the most common 
genetic alteration in human cancer, and forty different mutations have been identified 
(78). Mutations in the p53 gene are in some studies correlated to shortened survival in 
patients with cancer (79, 80), while other studies have shown a better prognosis  
(81, 82). Still other studies have not showed such correlation (78, 83). 
 
Ki-67 is an antigen that is a large protein and a marker for cell proliferation, that is, 
correlated to the proportion of cells in the S-phase in the cell proliferation cycle. The 
S-phase signifies the cells in mitosis, where the DNA in the cell nucleus is 
replicating. Molecular Immunology Borstel (MIB-1) is the antibody against Ki-67 
(84, 85). A majority of studies have shown a correlation between a higher expression 
of Ki-67 antigen and a worse prognosis in cancer patients (84, 85). 
 
1.5 CANCER OF THE OESOPHAGUS 
Cancer of the oesophagus is rare, representing only 0.8% of all new cases of cancer in 
Sweden 2004 (male: 1.1% and female: 0.4%) (86). Squamous cell carcinoma has long 
been the most common histological form of cancer in the oesophagus. For the past 
decade reports have shown a rising incidence of oesophageal adenocarcinoma in most 
of the western world. The incidence in Danish males has doubled since 1980, with 
more modest increases observed in the remaining Nordic countries. Among women, 
incidence has increased in Denmark, but remained stable in Sweden and Norway and 
declined in Iceland. The trends for mortality closely followed those of incidence. The 
age-standardized 5-year relative survival was at a low level throughout the period 
1964–2003, although it increased somewhat in more recent periods, particularly for 
Swedish men, where it reached 11% in 1999–2003, and for Swedish women, 14% 
(87). 
 
Esophageal cancer is an aggressive disease with surgery as an only chance for cure. 
The TNM classification system is traditionally used to stage oesophageal carcinoma. 
T1a lesions have less chance of nodal spread, with most series showing an incidence 
of nodal metastases of <10%, while about 30% of T1b lesions will have nodal 
metastases. In addition, the number of lymph nodes involved, histology, degree of 
differentiation, and location seem to have an impact on survival of patients with 
oesophageal cancer (88). Overall, more than 50% of patients have unresectable or 
metastatic disease at the time of presentation. The American Cancer Society’s Cancer 
2009 statistics state that the 5-year survival rate for all patients with oesophageal 
cancer is only 17%, with better survival for local (33.7%) or regional (16.9%) 
compared to distant (2.9%) disease at presentation (89). 
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Barrett’s oesophagus (BE) 
BE is characterized by replacement of squamous epithelium of distal oesophagus with 
specialized columnar epithelium with goblet cells, thought to be caused by damage 
from chronic acid exposure, or reflux oesophagitis. Oesophageal adenocarcinoma 
(Ac) develops in approximately 0.5% of patients with BE per year, and has a poor 
outcome unless diagnosed early. However, in 10–30% of patients with Ac, BE is not 
found. It is now generally accepted that Barrett’s epithelium can progress through a 
metaplasia-dysplasia-carcinoma progression but the natural history of dysplasia in 
Barrett’s oesophagus is not well defined. Identification of high-grade dysplasia 
(HGD) has been considered an indication for oesophagectomy or aggressive 
endoscopic treatment, since occult invasive cancer has frequently been identified at 
the time of resection. Without treatment, invasive cancer develops within 3 years in 
up to half of patients with HGD (90). 
 
The current clinical management of Barrett’s oesophagus is hampered by the lack of 
accurate predictors of progression. In addition, when patients develop cancer, the 
current staging modalities are limited to stratifying patients into different prognostic 
groups in order to guide the optimal therapy for an individual patient. Biomarkers 
have the potential to improve radically the clinical management of patients with 
Barrett’s oesophagus and oesophageal adenocarcinoma, but have not yet entered 
mainstream clinical practice. This is in contrast to other cancers like breast and 
prostate for which biomarkers are utilized routinely to inform clinical decisions. 
 
DIAGNOSIS OF OESOPHAGEAL CANCER 
Upper endoscopy is the gold standard for the diagnosis of oesophageal carcinoma. 
While the presence of a mass or a nodule is diagnosed via an upper endoscopy (and 
presence of cancer proven by biopsy), the depth of the tumour and lymph node 
involvement cannot be assessed with this modality. 
 
Computed Tomography. The sensitivity and specificity of CT in diagnosing 
locoregional nodal involvement are 84% and 67%, respectively. For distant organ 
metastases, the sensitivity is 81% and the specificity is 82% (91). CT has the 
limitation of diagnosing overgrowth of the tumour to adjacent organs, detecting small 
tumours of <1 cm and growth to different layers in the oesophageal wall. 
 
FDG-PET. This method has recently been introduced into oesophageal cancer 
staging and is more accurate than conventional CT imaging, particularly in the 
detection of distant metastases, and the combination of 18F-FDG-PET/CT is more 
accurate than CT alone with respect in diagnosing lymph node metastasis close to the 
tumour, and therefore staging (92). Despite the high sensitivity in detecting 
oesophageal cancer with 18F -FDG-PET/CT (92), these methods lack specificity; an 
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elevated 18F-FDG uptake could be seen in different non-malignant conditions, such as 
inflammation and Barrett’s oesophagus (46, 47, 71, 72, 93). 
 
A systematic review has shown a moderate sensitivity and specificity of 51% and 
84%, respectively, for the detection of locoregional lymph node metastases, and a 
sensitivity and specificity of 67% and 97%, respectively, for detection of distant 
metastases (94). 
 
Endoscopic ultrasound (EUS) is the most accurate non-invasive test for 
locoregional staging of oesophageal cancer (T and N classification), though 
distinguishing between early lesions (T1a and T1b) remains problematic. The overall 
accuracy of EUS for T classification is 84% (94). Rounded, sharply demarcated, 
homogeneous, and hypoechoic features of a lymph node on EUS indicate 
malignancy. The overall accuracy of EUS staging of locoregional nodal disease is 
77%. The addition of fine needle aspiration (FNA) to EUS further refines the staging 
of nodal disease, bringing the accuracy up to 85%, (95). EUS is superior to FDG-
PET/CT with respect to diagnosing the tumour growth through different layers in the 
oesophageal wall, overgrowth to adjacent organs, and lymph node metastasis close to 
the tumour (92, 96–98). 
 
Minimally invasive staging. The use of minimally invasive staging (laparoscopy or 
thoracoscopy) is not widely practised, because of the improving accuracies of 
noninvasive methods. Staging laparoscopy can be performed prior to performing a 
minimally invasive oesophagectomy or definitive resection. Laparoscopy is useful for 
detecting and confirming nodal involvement and distant metastatic disease that 
potentially would alter treatment and prognosis in patients with oesophageal cancer. 
Laparoscopy was reported to change the planned therapeutic approach in 10–17% of 
patients (99). 
 
SSTRS with 99mTc-depreotide in patients with oesophageal cancer 
We have previously used scintigraphy with 99mTc-depreotide for the diagnosis of lung 
cancer, and showed an accurate discrimination between benign and malignant lesions 
with conventional gamma cameras (46–48). There was a physiologically low 99mTc-
depreotide uptake in the thorax region. Therefore, visualization of overexpression of 
SSTRs in cancer types other than lung cancer should, theoretically, be feasible. 
Moreover, our previous results showed that this tracer accumulates both in squamous 
cancers and in adenocarcinomas (11), which is of clinical relevance in view of the 
almost exponential increase in the incidence of adenocarcinoma in the distal 
oesophagus. As of today there are no studies with SSTRS in patients with 
oesophageal carcinoma. 
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2 AIMS OF THE STUDY 
 
To establish the sensitivity and specificity of the somatostatin receptor scintigraphy 
with 99mTc-depreotide in patients with suspected lung cancer and to determine in 
which clinical settings it would be beneficial to use this method. 
 
To investigate whether there is an expression of SSTR2 in NSCLC estimated in vitro 
and to determine whether in vivo estimated 99mTc-depreotide uptake reflects the in 
vitro expression of SSTR2 in NSCLC. Also, to determine whether there is a 
correlation between 99mTc-depreotide uptake and the following prognostic factors in 
patients with NSCLC: tumour grade, presence of MIB-1, and p53. 
 
To evaluate whether oesophageal cancer could be detected scintigraphically with 
99mTc-depreotide and to determine the optimal imaging settings. Also, to investigate 
the uptake characteristics of 99mTc-depreotide of the main two cancer types of the 
oesophagus and relate that to patients with Barrett’s oesophagus. 
 
To investigate whether there is an expression of SSTR2A, SSTR2B, SSTR3, and 
SSTR5 in oesophageal cancer estimated in vitro and to determine whether in vivo 
estimated 99mTc-depreotide uptake reflects the in vitro expression of SSTR2A, 
SSTR2B, SSTR3, and SSTR5 in oesophageal cancer. 
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3 MATERIAL AND METHODS 
The Ethics Committee at Stockholm Region and the Radiation Protection Committee 
at the Karolinska University Hospital, Huddinge, approved all studies. 
 
3.1 SUBJECTS 
3.1.1 Study I and Study II, lung cancer patients 
All patients referred to the Department of Respiratory Medicine and Allergy at 
Karolinska University Hospital, Huddinge, with suspected lung cancer between April 
2002 and January 2004 were asked to participate in the study. After informed 
consent, 128 consecutive patients were included. No confirmation of pathology was 
obtained in one patient and because of loss of follow-up he was subsequently 
excluded. Among the 127 patients, 28 patients were included in a pilot study from 
April 2002 to March 2003. The remaining 99 patients were evaluated in Study 1. 
There were 47 women and 52 men with a median age of 66 years (range between 31 
to 86 years). Sixty-seven patients were smokers, 18 were ex-smokers who had quit 
for more than one year, and 14 had never smoked. 
 
Among these 127 patients, 19 patients with non-small-cell lung cancer were operated 
on and tissues samples from the tumours were analysed in vitro with reference to 
histopathological classification according to the World Health Organisation. Besides 
standard staining, an immunohistochemical evaluation was performed and these 
patients are included in Study II. 
 
3.1.2 Study III and Study IV, oesophagus cancer patients 
Thirty-four patients suffering from dysphagia were referred to the Department of 
Surgical Gastroenterology at Karolinska University Hospital, Huddinge, and further 
examined with gastroscopy, EUS, and CT. Of these, 9 were females and 25 males 
with a median age of 63.5 years (range from 33 to 85 years). Among the 34 patients, 
21 had cancer of the oesophagus and 13 had Barrett’s oesophagus. The cancer 
diagnosis was established by histopathological examination of biopsy specimens in 
19 cases, and with EUS and cytological confirmation of diagnosis in 2 cases. All 
patients with Barrett’s oesophagus had the diagnosis made at endoscopy and 
subsequent multiple biopsies. 
 
All specimens were classified as well differentiated (grade = G1), moderately 
differentiated (G2), or poorly differentiated (G3). 
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3.2 METHODS 
3.2.1 Scintigraphy 
For the somatostatin receptor scintigraphy, 99mTc-depreotide (NeoSpect, GE 
Biosciences, Sweden) was prepared in accordance with the manufacturer’s 
instructions, and 740MBq 99mTc-depreotide was injected into an antecubital vein. For 
Study I and Study II an examination was performed with a double-headed gamma 
camera (Sopha Medical Vision Scandinavia AB, DST-XL, General Electric, 
Milwaukee, WI, USA) equipped with low-energy, ultra-high resolution, parallel-hole 
collimators. For Study I all patients were examined with whole-body scanning and 
SPECT of the thorax within 2 to 4 hours after injection. The patient’s arms were 
elevated during SPECT and placed alongside his or her body during whole-body 
scanning. SPECT was done at 64 angles using a 128 × 128 matrix with 40 seconds 
per angle. Transverse slices were calculated with an iterative algorithm (HOSEM 
iterative program; Hermes/NUD; Stockholm, Sweden) into a 128 × 128 matrix 
without attenuation correction. Images were post-filtered with 3D Fourier filter 
(Butterworth filter with a cut-off frequency of 0.65 cycles/cm order 5.00). In addition 
to the transversal images, coronal and sagittal 3 mm images of the thorax were 
reconstructed. 
 
At the time of Study III and Study IV new data were published suggesting a double-
phase procedure with SSTRS as increasing methods specificity (47). For that reason, 
Study III and Study IV SPECT was performed as a double-phase procedure with 
imaging of the thorax at 2 and 4 hours after injection. Three different gamma cameras 
were used. Most of the patients (25 of 34) in Study III and (20 of 28) in Study IV 
were examined with a double-headed gamma camera (E-Cam, Siemens, Erlangen, 
Germany) and low-energy, high-resolution parallel-hole collimators, using a 128 × 
128 matrix, 64 projections through 360º rotation, and an acquisition time of 40 s per 
projection. An additional 5 patients in both Studies III and IV were examined with a 
double-headed gamma camera (DST-XL; Sopha Medical Vision Scandinavia AB, 
Gif-sur-Yvette, France) and low-energy, ultra-high-resolution, parallel-hole 
collimators, using the same acquisition parameters as above. Finally, 4 patients (in 
Study III) and 3 patients (in Study IV) were examined with a three-headed gamma 
camera (Picker IRIX, Cleveland, OH, USA) and low-energy, high-resolution, 
parallel-hole collimators, using a 128 ×128 matrix, 60 projections through 360º 
rotations, and an acquisition time of 64 s per projection. Transverse slices were 
reconstructed with an iterative algorithm (HOSEM v 3.5 iterative program; 
Hermes/NUD, Stockholm, Sweden) and formatted as a 128 × 128 matrix without 
attenuation correction. Images were post-filtered with a three-dimensional Fourier 
filter (Butterworth filter) with a cut-off frequency of 1.1 cycles/cm (order 5.00). 
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3.2.1.1 Evaluation of scintigraphic images 
The scintigraphic images were evaluated both through visual assessment (Study I) 
and through quantitative calculations (in Studies II–IV). Two experienced 
radiologists, one of whom is also a nuclear medicine specialist, evaluated the 
scintigrams. The readers were not told of the final diagnosis but were given the 
radiological findings. The scintigrams were evaluated along with CT, since the 
reading of the scintigrams requires anatomical landmarks given at the CT 
investigation (100). 
 
Any visually observed focal accumulation of the 99mTc-depreotide in the lung 
parenchyma compared to that of a normal lung was considered as a pathological 
uptake in patients with suspected lung cancer (Study I and II). 
 
Focal accumulation of the 99mTc-depreotide in locations other than the lung 
parenchyma was also registered both with regard to the whole-body images and to the 
transversal, coronal and sagittal images of the thorax (Study I). 
 
For Studies III and IV any focal 99mTc-depreotide uptake in the region of the known 
oesophageal lesion was considered pathological. 
 
The quantitative measurements of the 99mTc-depreotide uptake (Study II–IV) were 
made on the SPECT transverse slice images with Hermes computer system by 
manually drawing a region of interest (ROI) around the lung tumour (Study II) or 
around the oesophageal tumour (Study III and IV) and by drawing one ROI with the 
average uptake on the patient’s lung parenchyma for background subtraction. The 
lung parenchyma was chosen as a reference region, as it is known that a normal lung 
parenchyma as well as brain and muscles show very low expression of SSTRs (101). 
A volume of interest (VOI) was obtained by adding all ROIs. In-house software, 
originally developed for volumetric measurements in magnetic resonance images and 
implemented on a Hermes workstation (Hermes Medical Solution AB, Stockholm, 
Sweden), was used to calculate the total counts and volume of the tumour and 
background VOIs, thus giving a count density [counts/cm3]. To produce a normalized 
tumour uptake, each patient was normalized to his or her own normal lung 
parenchyma using the formula   BBTU  , where U is the normalized uptake, T is 
the count density in the tumour, and B is the count density in the lung parenchyma. 
For patients with negative uptake (i.e. tumour count density lower than the lung 
background count density), the uptake was scored as zero (Study II–IV). 
 16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                         b) 
 
Figure 1. Evaluation of 99mTc-depreotide uptake in oesophageal carcinoma 2 (a) and 4 (b) 
hours after injection. 
 
To increase accuracy and to investigate the intra-observer variability (Study III and 
IV), evaluations were performed twice, 6 months apart, by the same radiologist, and 
the mean value of the two uptake values was used in further analysis. In addition,  
a second radiologist made individual evaluations in order to investigate the inter-
observer variability of the uptake values seen in images taken at 2 hours. 
 
3.2.2 Computed tomography (CT) 
CT of the thorax and upper abdomen was performed in all patients in this thesis as a 
part of routine examination. For Studies I and II all lung lesions (127 patients) were 
detected by CT, performed between April 2002 and January 2004. The median 
interval between CT and scintigraphy in Studies I and II was 4 four weeks. 
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The CT investigations were done both at our hospital (n = 79) and at external 
departments (n = 20). At our hospital, 46 scans were performed with the multi-slice 
spiral CT Somatom Volume Zoom (Siemens, Erlanger, Germany), slice thickness 4 × 
1 mm, pitch 1.5, and 33 scans with the spiral CT single-slice Tomoscan AVE1 
(Philips Medical Systems, Einthoven, the Netherlands) slice thickness 5 mm, pitch 
1.5. Images were reconstructed with 5 mm slices in the mediastinum and 10 mm in 
the lung from both CTs. Contrast media (120 mL) was injected intravenously, and all 
scans were done while the patients were holding their breath. The CT technology at 
the external hospitals was essentially the same as at our department. 
 
The CT/chest X-rays were evaluated by two experienced radiologists according to 
established criteria such as size, calcium and fat content, and the shape and borders of 
the pulmonary lesions. The age of the patient, smoking habits, and growth rate typical 
of cancer, as well as signs of invasiveness or metastatic spread, were noted (102). 
Based on this analysis the probability of lung cancer was graded on a scale from 1 to 
3 (Table 1), where a benign lesion was considered 1, indeterminate was considered 2, 
and a malignant lesion was considered 3. 
 
Table 2. (Study I) Criteria used for CT grading of the radiological probability of malignancy. 
 
Group Radiological findings 
 
Radiological diagnosis 
1  No solid lesion or infiltration resolved since 
previous chest radiography/CT.A lesion less than 
2 cm in size, fat containing, with popcorn-like 
calcifications, smooth margin, and a sharply 
defined edge located in upper lobe. No growth for 
more than 2 years when compared with previous 
examinations. 
Benign 
2 A single solid lesion with or without fat or 
calcifications, with or without cavitations, located 
anywhere in the lung. No enlarged lymph nodes, 
no coexisting lung lesions. No previous 
examinations exist or no growth during previous 
6 month. 
Indeterminate 
3 A solid lesion more than 2 cm in size, without fat 
or calcifications, irregular contour as well as 
speculated margin, cavitations with thick, 
irregular wall, located anywhere in the lungs. 
Lesion penetrating surrounding tissues, such as 
vessels and bone. Enlarged lymph nodes, multiple 
coexisting lung lesions in both lungs. Lesion 
growth during last 6 month when compared with 
previous examinations. 
 
Malignant 
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3.2.3 PET/CT 
Some patients in Study I and in Study III were investigated with PET/CT at 
Karolinska University Hospital, Solna using a Biograph 64 TruePoint PET/CT 
scanner (Siemens Medical Solutions, Erlangen, Germany). All patients fasted for at 
least 6 h before the examination. After 1 h rest, 4 MBq/kg bodyweight (bw) of [18F]-
2-fluoro-2-deoxy-D-glucose (FDG) was administered intravenously. One hour later,  
a PET/CT examination from the middle skull to the proximal thigh was initiated. 
 
Serum glucose levels were routinely measured to ensure that all patients had a normal 
serum glucose level at the time of examination (G7.0 mmol/L). Diabetic patients were 
generally instructed to keep their regular schedule of glucose-controlling drugs. The 
examination started with a low-dose CT without administration of contrast medium 
for correction of photon attenuation and scattering. Directly upon this, the PET 
examination was made using a full-ring dedicated scanner with an axial field-of-view 
of 21.5 cm. Acquisition was made during 3 min at each bed position during normal 
tidal breathing. Images were reconstructed with CT-based attenuation and scattering 
corrections using the iterative ordered subsets expectation maximum reconstruction. 
A full-dose CT with and/or without administration of intravenous contrast medium 
was performed directly afterward by a continuous spiral 64-slice technique with a 
voltage of 120 kV, a pitch of 0.8, a slice thickness of 1.2 mm, and a rotation speed of 
0.5 s per revolution. In the acquisitions made for photon attenuation and scattering 
correction, the current was 50 mA•s, while otherwise the tube current modulation 
routine was applied. Examination was made while breath holding at a mean 
inspiratory level. For contrast enhancement, Ioversol (Optiray® 350 mg I/mL, Tyco 
Healthcare Deutschland GmbH, Neustadt/Donau, Germany) was used. The dose was 
1 mL/kg bw. In patients 970 kg bw, 10 mL of contrast medium was added. The 
injection speed was 1.5–2.5 mL/s. 
 
3.2.4 EUS 
EUS was performed by way of gastroscopy with an ultrasound probe. All EUS 
procedures were accompanied with fine needle biopsy. There are two kinds of 
electronic echo endoscope, the radial and the linear. The radial gives an image in 360 
degrees that is perpendicular to the instrument, while the linear gives an image 
parallel to the axis of the instrument. Only the linear provides a guidance to biopsy. 
The frequencies used are higher than for ordinary transabdominal ultrasound; 
frequencies used are between 5 to 30 MHz. The higher the frequency, the higher the 
resolution will be with the lower penetration and vice versa. The patient fasts before 
the examination and the examination takes between 15 and 60 minutes to perform 
(103). 
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3.2.5 Immunohistochemistry 
For determining the somatostatin receptor 2A (SSTR2A) (Study II) we used an 
antiserum raised from the sequence of the C-terminal portion of this somatostatin 
receptor (Gramsch Laboratories, Schwabhausen, Germany). For MIB-1 receptor 
determination the monoclonal Mouse Anti-Human Ki-67 Antigen, clone MIB-1 
(DakoCytomation, Glostrup, Denmark) was used. For p-53 receptor determination the 
monoclonal Mouse Anti-Human p53 Protein, clone DO-7 (DakoCytomation, 
Glostrup, Denmark) was used. The antibody against SSTS2A was applied to tissue 
sections at a dilution of 1/20000. The anti-MIB-1 antibody was applied at a dilution 
of 1/80. The anti-p53 antibody was applied at a dilution of 1/40. The immuno-
peroxidase technique using the streptavidin-peroxidase kit (DakoCytomation) was 
used to reveal the immune reactions. 
 
For MIB-1 and p53, the number of positive nuclei was calculated on 10 randomly 
chosen areas of the tumour histological sections and the result expressed as 
percentage. 
 
To evaluate the positivity of SSTR2A, an image analysis method was used. Applying 
the HIS (hue, saturation, and intensity) model (Gonzales) the saturation of the 
immunoperoxidase stain was calculated (range 0–1), and SSTR2 expression was 
graded on a three-point scale, with one representing the lowest expression. To avoid 
bias due to background influence, the mean value calculated in the normal bronchial 
epithelium was subtracted from the value of the tumour positive areas. The algorithm 
was written by one of us (AC). 
 
The procedure was different in Study IV. For immunohistochemical assessment of 
the different SSTRs (2A, 2B, 3, and 5), the Bond system (Vision Bio Systems Ltd. 
Australian, Melbourne) was used. Tissue specimens of the oesophageal tumours and 
biopsy material from the patients with Barrett’s oesophagus were processed and 
prepared for immunostaining by use of monoclonal antibodies. The pretreatment to 
achieve the epitope was performed by heat treatment and with the enzyme pronase. 
The tissue sample was first treated with peroxidase. The antibody was diluted 1000 
times and the enzyme pronase was diluted 50 μL in 7000 μL. The tissue sample for 
SSTR2A and SSTR2B was pretreated with the diluted enzyme solution and with the 
enhancer for 10 min. The tissue sample for SSTR3 was pretreated with H1 = Citrate 
buffer pH = 6, without enzyme and without enhancer for 20 min, and the tissue 
sample for SSTR5 was pretreated with H2 = EDTA buffer pH = 9 without enzyme 
and without enhancer for 40 min. 
 
After this pre-treatment the samples were incubated with the antibodies for 30 min 
and the incubation temperature was between 37 and 100ºC. The development was 
then performed with diaminobenzidine (DAB) and then stained with hematoxylin. 
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The Bond Polymer Refine Detection System was a compact polymer system with 
high sensitivity where peroxide block, intensive DAB dyeing, and hematoxylin 
contrast dyeing was included. This gave the dyeing high intensity combined with a 
sharp definition, without the use of streptavidin and biotin. By this, it was excluded 
that non-specific dyeing occurs because of the presence of endogenous biotin, which 
occurs in large amounts in some tissues in the gastrointestinal channel. During testing 
of the antibodies, pancreas and skin were used as a positive control to exclude false 
positive results. Both positive and negative controls were used at the incubation and 
dyeing steps. 
 
SSTR2A/SS800 was the antibody against the SSTR2A, SSTR2B/SS860 was the 
antibody against SSTR2B, SSTR3/SS850 was the antibody against SSTR3, and 
SSTR5/SS890 was the antibody against SSTR5. The enhancer was a copper 
intensification. The buffers used were H1 = Citrate buffer pH = 6 and H2 = EDTA 
buffer pH = 9. 
 
The (SSTR) concentration was graded as no receptor presence = 0, small 
amounts = 1, moderate amounts = 2, and large amounts = 3. 
 
3.2.6 Statistics 
Study I. Sensitivity and specificity of SSTRS with 99mTc-depreotide in lung cancer 
diagnosis were evaluated in this study. Sensitivity is the number of true positive test 
results compared to all positives. Specificity is the number of true negative test results 
compared to all negatives. 
 
Study II. Extreme values may bias results when only two variables are being 
examined; relationships between tumour grade, 99mTc-depreotide uptake, SSTR2 
expression, MIB-1, and p53 receptors were therefore analysed using Spearman Rank 
order correlations. The resulting correlation coefficients with corresponding p-values 
were calculated, and the correlation coefficient was considered significant if the 
corresponding p-value was 0.05 or less. 
 
Study III. Due to the small number of patients in each group, a non-parametric test 
was chosen. A two-sided Mann-Whitney U test was used to investigate the difference 
in uptake between malign and benign tumours, implemented in Statistica 9.0 (StatSoft 
Inc., Tulsa, OK, USA). Data were analysed based on both the 2-hour and the 4-hour 
post-injection recordings. A difference in uptake was considered significant if the p-
value was less than 0.05. To assess intraobserver and interobserver variability, 
intraclass correlation coefficients (ICC) were determined. 
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Study IV. Because extreme values may bias results when only two variables are 
being examined, relationships between 99mTc-depreotide uptake, tumour grade, and 
amount of the different studied SSTRs were analysed using Spearman rank 
correlations. Corresponding p-values were calculated and considered significant if the 
p-value was less than 0.05. 
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4 RESULTS 
The findings from the different studies are summarized below. 
 
4.1 STUDY I  
This study was conducted after the results of our pilot study showed the rationale of 
the use of 99mTc-depreotide in patients with suspected lung cancer. The sensitivity of 
SSTRS with 99mTc-depreotide was 94% to detect malignancy and 98% to detect lung 
cancer. The specificity was calculated on two sets of data - when all cases are used, 
the specificity is 52%. If the 12 pneumonias are excluded, the specificity is 77%. The 
diagnostic accuracy of the method in different settings is presented in Table 3. 
 
Of the total of 66 malignancies, 62 were positive on 99mTc-depreotide scintigraphy, 
thus true positive n = 62, yielding a sensitivity of 94%. Of the 58 lung malignancies, 
57 were positive on 99mTc-depreotide scintigraphy, yielding a sensitivity of 98%. 
Among the other 8 malignancies with origin other than the lungs, 5 were positive on 
99mTc-depreotide scintigraphy: these were 2 lymphomas, 2 malignant melanomas, and 
1 breast cancer metastasis. 
 
Only one lung cancer was negative on 99mTc-depreotide scintigraphy, this one a 1 cm 
bronchioloalveolar carcinoma situated in the apex of the left upper lobe. Three of the 
malignancies with origin other than the lungs were negative on 99mTc-depreotide 
scintigraphy. These were a rectal cancer metastasis, an adenoid cystic cancer 
metastasis, and the rib chondrosarcoma case). A chondrosarcoma is not a lung 
tumour, but it occurred in the thorax and was mistaken for one, which is why it was 
still retained for the assessment of the method. Thus there were false negative n = 4. 
There was no focal 99mTc-depreotide uptake in 17 of 33 patients with benign diseases, 
true negative n = 17. These were all 10 hamartomas, 1 pneumonia, 1 pleuritis,  
1 sarcoidosis, 1 granuloma, 1 granulomatous inflammation, and 2 benign lesions 
which were probably hamartomas. 
 
There was 99mTc-depreotide uptake in 11 of the 12 pneumonias, in 1 fibrosis, in 2 
round atelectases, 1 pleural fibrosis, and 1 pneumoconiosis. Thus false positive 
n = 16. 
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Table 3. Diagnostic accuracy of scintigraphy with 99mTc-depreotide. 
 Whole study 
population 
N = 99 in % 
Lung cancer and 
benign lesions 
N = 91 in % 
All lesions except 
pneumonias 
N = 87 in % 
 
Sensitivity 94 98 94 
Specificity 52 52 77 
Accuracy 80 81 89 
NNP 91 94 81 
PPV 79 77 93 
NPV = negative predictive value. PPV = positive predictive value. 
 
4.1.1 Correlation between CT and scintigraphy with 99mTc-depreotide 
All 51 cases radiologically graded as ‘malignant’ showed 99mTc-depreotide uptake 
(i.e. 50 were true positives and 1 was a false positive). More than 1/3 of all lesions in 
this study were graded as radiologically ‘indeterminate’ (n = 39). Among these 
lesions, 16 were malignant, and 99mTc-depreotide uptake was found in 12 of them. It 
was absent in 3 patients with metastatic disease and in a patient with 
bronchioloalveolar carcinoma. In the group of radiologically ‘indeterminate’ lesions 
23 were benign and 99mTc-depreotide uptake was absent in 13 of them (i.e. true 
negatives), while 10 cases showed 99mTc-depreotide uptake and were classified as 
false positives. Among these 10 cases, 8 were pneumonias, 1 was pleural fibrosis, and 
1 pneumoconiosis. If pneumonias are excluded, the number of false positives falls to 
two. Of nine ‘probably benign’ lesions, five (3 pneumonias and 2 round atelectasis) 
showed 99mTc-depreotide uptake and were false positives. 
 
4.1.2 Extra pulmonary 99mTc-depreotide uptake 
There was 99mTc-depreotide uptake in 204 regional lymph node stations, in patients 
with both malignant and benign lesions with a sensitivity of 99%, and a negative 
predictive value of 98% in determining metastatic lymph node involvement. These 
data were evaluated separately and are not included in this thesis (75). There was also 
a focal uptake in locations other than the lung or the mediastinum in 21cases. 
Depending on the clinical situation, some of these findings were further evaluated. 
Four patients with lung cancer showed uptake in supraclavicular lymph nodes, 
diagnosed by fine-needle aspiration as metastases from adenocarcinoma (n = 2) 
or/and squamous cell lung cancers (n = 2). Focal uptake in the bones represented 
morphologically verified metastases (n = 2), large osteophytes (n = 2), or 
degenerative changes (n = 2) on CT. There was uptake in the thyroid in one case of 
Hashimoto’s thyreoiditis and in another case of well-substituted hypothyreosis. One 
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case with an adenocarcinoma of the lung had two focal uptakes in the brain, one 
representing a metastasis and the other a meningioma. In one case of small-cell-lung 
cancer there were multiple small brain metastases on the CT, but no depreotide 
uptake was detected in the whole body images. Metastases in the liver, adrenals, and 
kidneys are difficult to detect because of a physiological high 99mTc-depreotide 
uptake in these regions. This was the case in four patients with proven metastasis in 
the adrenals and one patient with liver metastasis. Neither was a 2 cm metastasis in 
the pancreas detected. A 4 cm fibroadenoma of the breast had no uptake. As 
previously described, there was an unspecific 99mTc-depreotide accumulation in 
axillary sweat glands, not to be mistaken for metastasis (104). 
 
4.2 STUDY II 
Correlation between 99mTc-depreotide uptake and immunohistochemically analysed 
surgical specimens for SSTR2, p53, and MIB-1 was performed in 19 patients with 
non-small-cell lung cancer (Table 4). 
 
The level of SSTR2 expression was positively correlated with the degree of tumour 
differentiation (i.e. the higher the level of SSTR2 expression, the more G1 tumours or 
well-differentiated tumours). This correlation was significant (p < 0.05), correlation 
coefficient (CC) = 0.81.There was no correlation between p53 expression and tumour 
grade and no correlation between p53 expression and 99mTc-depreotide uptake. 
 
In contrast, MIB-1 expression was negatively correlated with tumour grade, (i.e. the 
higher the level of MIB-1 expression, the fewer G1 tumours or well-differentiated 
tumours). This correlation was significant (p < 0.05), CC = −0.46. There was also a 
slight but significant negative correlation between SSTR2 and MIB-1 expression (p < 
0.05), CC = –0.57). 
 
There was no correlation (p > 0.05) between tumour grade, SSTR, MIB-1, or p53 
expression, either absolute or relative to background 99mTc-depreotide uptake in 
tumour cells. 
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Table 4. Histological parameters versus 99mTc-depreotide uptake in 19 patients with  
non-small-cell lung carcinoma. 
 
Patient 
number 
Diagnosis Diff. 
grade 
MIB-
1 
P53 SSTR2 Total 
uptake (T) 
Counts/cm3 
Background 
(B) 
Counts/cm3 
T-
B/B 
1 Ac 1 3 5 3 1,216,309 517,013 1.353 
2 Ac 2 8 25 2 553,900 339,950 0.629 
3 Ac 1 4 0 3 917,689 484,209 0.895 
4 Ac pap 1 3 0 2 935,053 449,801 1.079 
5 Ac pap 1 78 0 1 930,637 409,165 1.274 
6 Ac 3 92 80 1 871,396 442,596 0.969 
7 Ac muc 3 70 42 1 1,752,289 521,677 2.359 
8 Ac 2 50 95 2 525,631 249,345 1.108 
9 Ac LC 3 63 70 1 645,724 319,381 1.022 
10 Ac 1 12 0 2 551,742 381,868 0.445 
11 Sq 2 16 84 2 384,114 219,341 0.751 
12 Sq 2 75 93 2 796,728 419,504 0.899 
13 Ac 2 64 99 2 1,090,793 520,498 1.096 
14 Ac 3 6 11 1 1,255,699 245,327 4.118 
15 Sq 3 87 0 1 401,167 168,640 1.379 
16 Ac LC 3 18 71 1 409,694 314,048 0.305 
17 Ac 3 10 0 1 565,961 348,891 0.622 
18 Neu 3 70 0 1 561,902 364,039 0.544 
19 Ac bac 1 10 0 3 289,120 145,225 0.991 
SSTR2 are somatostatin receptors subtype 2, and the amount of these receptors are graded as 0 to 3, 
where 0 is no presence and 3 is the highest amount. Differentiation grade is differentiation of the tumour, 
graded from 1 to 3, where 3 is the lowest differentiation, that is, the most malignant tumour. Diagnoses: Ac 
= adenocarcinoma, acinar type; Ac pap = adenocarcinoma, papillary; Ac muc = adenocarcinoma, 
mucoepidermoid; Ac LC = adenocarcinoma, large-cell carcinoma; sq = squamous cell carcinoma; neu = 
neuroendocrine pulmonary carcinoma, mixed type; and Ac bac = adenocarcinoma, non-mucinous 
bronchioloalveolar carcinoma. 
 
 
4.3 STUDY III 
This study showed that it is feasible to image oesophageal cancer with labelled 
somatostatin analogue. Among 34 patients with oesophageal lesions, 21 had cancer 
and 13 were benign. Of these 21 patients, 16 had pathological uptake of 99mTc-
depreotide (true positive 76%) and 5 were negative (false negative 24%) on visual 
assessment. Six of the 8 patients with SqCC and 5 of the 11 patients with Ac showed 
a pathological 99mTc-depreotide uptake. The remaining 5 patients had false negative 
uptake of 99mTc-depreotide (Table 5). The sensitivity of 99mTc-depreotide scintigraphy 
in the detection of oesophageal cancer was thus 76%. 
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a) 
 
b) 
  
c) 
Figure 2. Cancer in the upper part of oesophagus: transversal slice on CT, (a) FDG-PET/CT 
(b), and 99mTc-depreotide SPECT (c). 
 
There was no 99mTc-depreotide uptake in the columnar metaplastic mucosa in any of 
the 13 Barrett’s patients, irrespective of the presence of low- and high-grade dysplasia 
in the metaplastic epithelium on visual assessment. The specificity of 99mTc-
depreotide scintigraphy in this cohort of patients was thus 100%.  
 
There was no significant difference in uptake of 99mTc-depreotide between 2 hours 
and 4 hours ROI delineation and quantitative measurement. A corresponding second 
ROI delineation and quantification, performed 6 months later, gave consistent results. 
Both intraobserver and interobserver variability was low, with ICC = 0.97 when 
comparing the evaluations by the same radiologist (intra-observer), and ICC = 0.96 
when comparing the evaluations made by the two radiologists (inter-observer). 
 
A statistically significant difference (p < 0.005) was found between 99mTc-depreotide 
uptake in malignant lesions compared to that in benign or premalignant lesions 
(Figure 3), both 2 and 4 hours after injection. The absolute 99mTc-depreotide uptake 
value was also higher in all malignant lesions after 2 compared to 4 hours. There was 
no difference in uptake between Ac and SqCC. 
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Table 5. Tumour type, size, and location; CT result; and 99mTc-depreotide uptake  
in 21 oesophageal cancer patients. 
 
N Diagnosis Tumour size  in mm Location CT 
99mTc-
depreotide 
1 Sqcc 5 Middle Neg. Neg. 
2 Ac 17 × 45 Distal Pos. Pos. 
3 Sqcc 55 × 40 Proximal Pos. Pos. 
4 Ac in B 65 × 55 × 13 Distal Pos. Pos. 
5 Ac 90 × 75 × 25 Distal Pos. Pos. 
6 Imc and B 12 × 9 Distal Neg. Neg. 
7 Sqcc 30 × 10 Middle Pos Pos 
8 Ac 20 × 90 Middle Pos. Pos. 
9 Ac 60 × 25 × 9 Distal Pos. Pos. 
10 Sqcc 50 × 45 Distal Pos. Pos. 
11 Small-cell cancer 110 × 24 Middle Pos. Pos. 
12 Ac in B 60 × 65 Distal Pos. Pos. 
13 Ac 25 × 15 Distal Neg. Pos. 
14 Ac in B 20 × 25 Distal Pos. Pos. 
15 Sqcc 60 × 10 Proximal Pos. Pos. 
16 Sqcc 15 × 55 Distal Pos. Pos. 
17 Ac 15 × 50 Distal Pos.  Pos. 
18 Ac 15 × 15 distal Neg. Neg. 
19 Ac in B 20 × 25 Distal Neg. Neg. 
20 Sqcc 14 × 5 Middle Neg. Pos. 
21 Sqcc 23 × 38 × 12 Distal Pos. Neg. 
Ac = adenocarcinoma, Sqcc = squamous cell carcinoma, B = Barrett’s oesophagus, Imc = intramucosal 
cancer. 99mTc-depreotide uptake classified as negative or positive based on visual assessment. CT pos = 
tumour is visible on the CT images. CT neg = tumour is not visible on the CT images. 
 
The absolute 99mTc-depreotide uptake value was also higher in all malignant lesions 
after 2 compared to 4 hours. There was no difference in uptake between Ac and 
SqCC. 
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Figure 3 (Study III). 99mTc-depreotide uptake measured 2 hours after injection in patients with 
oesophageal cancer and Barrett’s oesophagus. 
 
Although this study was not designed to compare the 99mTc-depreotide scintigraphy 
with 18F-FDG-PET, we found it of more general interest to make such a comparison. 
Unfortunately, the number of patients who performed both images was not sufficient 
for any reliable statistical evaluation, especially of patients without malignancy, and 
these data were not included in our paper III, but are presented here. Besides, this data 
would not answer the main question of our study: Is it feasible to detect oesophageal 
cancer by SSTRS? 
 
Among the 34 patients in this study only 17 were also examined with PET/CT, of 
whom 15 had cancer and 2 had dysplasia in Barrett’s oesophagus without cancer. 
Among the 15 cancer patients examined with 18F-FDG-PET, uptake was found in 13. 
False negative results were found in intramucosal cancer in a case of Barrett’s 
oesophagus (12 × 9 mm) and a 5 mm SqCC. Both were missed with SSTRS with 
99mTc-depreotide, as well. 
 
There were 2 discordant results between these tracers, where SSTRS with 99mTc-
depreotide was less sensitive in 2 more cancers, both located in the distal part of the 
oesophagus: a 23 × 38 × 12 mm SqCC and a 20 × 25 mm Ac (Barrett’s). 
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Table 6. Head-to head comparison of results of SSTRS with 99mTc-depreotide 
and FDG-PET/CT. 
 
Diagnosis Depreotide uptake FDG PET 
Adenocarcinoma Barrett’s + + 
Adenocarcinoma Barrett’s + + 
Adenocarcinoma Barrett’s + + 
Adenocarcinoma Barrett’s - + 
Adenocarcinoma + + 
Adenocarcinoma + + 
Adenocarcinoma + + 
Squamous cell carcinoma - - 
Squamous cell carcinoma + + 
Squamous cell carcinoma + + 
Squamous cell carcinoma + + 
Squamous cell carcinoma + + 
Squamous cell carcinoma - + 
Intramucosal cancer, Barrett’s - - 
Cancer of small cell + + 
Dysplasia, Barrett’s - - 
Dysplasia, Barrett’s - - 
 
 
Our results in the detection of loco-regional lymph node metastases were 
unsatisfactory. Only 5 of 13 patients with metastases seen with EUS and confirmed 
by histological examination were clearly detected by 99mTc-depreotide scintigraphy. 
 
4.4 STUDY IV 
One radiologist measured values for 99mTc-depreotide uptake in April 2009 and 
October 2009, and a second radiologist measured these uptake values in November 
2010. Both intra-observer and inter-observer variability for the quantitative 
assessment of 99mTc-depreotide uptake in the oesophageal lesions were low, with the 
ICC being 0.97 and 0.96, respectively. 
 
Immunohistochemical detection and semiquantitative assessment of the different 
SSTRs in 11 patients with Ac are present in Table 7, and the 11 patients with 
Barrett’s oesophagus without cancer in Table 8. Among the 6 patients with SqCC 
only one patient displayed SSTR5 and the remaining 5 patients were devoid of 
SSTRs. Among the Ac patients, the majority expressed low amounts of SSTRs; one 
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patient had none, a few had moderate amounts, and only one patient expressed high 
amount of SSTR5 (Figure 4). 
 
Table 7. Histopathological and immunohistochemical analyses of adenocancer of the 
oesophagus. 
 
Patient 
no. 
SSTR2A SSTR2B SSTR3 SSTR5 Grade of 
differentiation 
Barrett’s 
2 1 1 1 1 intermediate - 
4 0 0 0 0 low yes 
5 1 0 1 1 low - 
6 1 1 1 1 high yes 
11 0 0 1 1 low - 
12 1 0 1 1 low - 
13 1 1 1 1 low yes 
14 1 1 1 1 high - 
15 1 1 1 3 low yes 
16 1 2 2 2 high yes 
17 2 2 2 1 intermediate yes 
SSTR expression was graded as none = 0, small amounts = 1, moderate amounts = 2  
and large amounts = 3. 
 
 
 
 
 
 
 
a) 
 
b) 
 
Figure 4. Strongly positive SSTR3 staining in well-differentiated Ac (a); negative SSTR3 
staining in poorly differentiated Ac of signet ring cell type (b). 
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Table 8. Immunohistochemical analyses of 11 Barrett’s patients without cancer. 
 
Patient no. SSTR2A SSTR2B SSTR3 SSTR5 
7 1 1 3 1 
8 1 1 3 - 
20 1 1 2 3 
21 1 - 1 - 
22 1 2 1 2 
23 0 0 0 1 
24 - 0 0 - 
25 1 1 1 2 
26 0 0 0 - 
27 1 0 1 1 
28 2 2 2 2 
SSTR expression was graded as none = 0, small amounts = 1, moderate amounts = 2, 
 and large amounts = 3. 
 
No correlation was revealed between the differentiation of the tumour and the 
expression of different SSTRs, either for the Ac or for the Sqcc. With the exception 
of a significant (p ≤ 0.05) correlation (r = 0.70) between the presence of SSTR2B and 
the grading of the Ac, the higher the amount of SSTR2B, the higher the grading of 
the tumour. 
 
Overall, the observed levels of SSTR2A, SSTR2B, SSTR3, and SSTR5 in Sqcc were 
significantly lower compared to Ac (p = 0.001, p = 0.019, p = 0.0002, p = 0.047, 
respectively). 
 
The majority of the patients with Barrett’s oesophagus expressed SSTRs in their 
columnar epithelium. The semiquantitative scoring on the abundance of SSTR did not 
reveal any difference in separation of epithelium between those with dysplastic 
morphological changes and those without. 
 
No correlation between the 99mTc-depreotide uptake and the expression of any of the 
examined SSTRs in the 17 patients with cancer of the oesophagus was found. As well 
as with lung cancers, there was a tendency for poorly differentiated tumours to have 
higher 99mTc-depreotide uptake compared to well-differentiated Ac tumours, but this 
difference did not reach statistical significance. 
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The SqCC seemed to express lower 99mTc-depreotide uptake compared to the 
adenocarcinoma, but this difference could not be statistically substantiated. 
Cases showing positive uptake with the scintigraphic method but negative results in 
the immunohistological analysis displayed no remarkable degree of inflammation on 
histopathological examination of the tissue specimens. Neither did we observe an 
SSRT immunostaining of the inflammatory cells present in the specimens. Not even 
the non-inflammatory cells (stroma cells, vessels, and others) did so. 
 
Among the patients with Barrett’s oesophagus, five had either high or low grade of 
dysplastic changes in the columnar epithelium. There was a tendency towards higher 
99mTc-depreotide uptake in the epithelium with dysplasia than in that without 
dysplasia, but this difference could not be statistically verified. 
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5 DISCUSSION 
The main objective of this thesis was to explore the value of somatostatin receptor 
scintigraphy with 99mTc-labelled analogue in patients with suspected lung or 
oesophageal cancer. 
 
5.1 LUNG CANCER 
The specificity in diagnosing lesions in the lungs is limited with the currently used 
methods; therefore surgery is performed on numerous patients with benign lesions. 
Previous studies with 99mTc-depreotide have shown promising results in 
differentiating malignant from benign lesions in the lungs (46, 47, 105, 106). To 
establish the role of scintigraphy with 99mTc-depreotide, a selected group of patients 
with a high probability of lung cancer was studied. 
 
In our Study I the sensitivity in detecting malignancy was 94%, and in detecting lung 
cancer, 98%. Thus, all lung cancers but one showed 99mTc-depreotide uptake. The 
exception was a 10 mm small bronchioloalveolar carcinoma. A false negative 
scintigraphic finding can be explained by factors such as size, location, and type of 
the tumour. 
 
A tumour of this size could be missed, if the difference in uptake between the tumour 
and the uptake in the surrounding tissue is small, and if the tumour is small the uptake 
will be diluted in a larger pixel volume, with lowering of the uptake due to partial 
volume effect. The lower spatial resolution the larger pixel volume. The spatial 
resolution with the SPECT method is 2 cm. In a European multicentre trial the 
sensitivity for this method was 93% for lesions >1.5 cm and dropped to 75% when 
the lesions were ≤1.5 cm (48). 
 
Another reason for false negative results could be the location of the tumour, for 
example, tumours situated caudally in the lower lobes close to the liver or spleen 
where the uptake could be hidden by physiological tracer uptake in the liver or spleen 
(46, 47, 48, 71, 105, 106, 107). 
 
A third possibility for false negative results could be the biological nature of the 
tumour, that is, the absence of SSTRs. In a study by Martinez et al. (47), the only 
missed lung carcinoma was of the same size and histological type as in our study, and 
in a study by Kahn et al. (71) two of the missed tumours were also of the same nature 
( e.g. bronchioloalveolar carcinoma) and related size. 
 
The specificity in our study was in the first calculation rather low, 52%, because of 
accompanying pneumonia. Therefore, we calculated the specificity after exclusion of 
the 12 pneumonias, which yielded a specificity of 77%. 99mTc-depreotide uptake in 
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inflammatory processes has been described (46, 47, 71, 48, 107) and may be the 
result of tracer uptake in activated lymphocytes and macrophages (46). Both in 
infectious and non-infectious granulomatous processes somatostatin receptors have 
been identified in epithelioid cells. Their presence may cause the false positive 99mTc-
depreotide uptake in round atelectasis (105, 108), granulomas (46, 106), and 
sarcoidosis (105). 
 
In our study scintigraphy with 99mTc-depreotide showed a high negative predictive 
value (94%) for excluding malignancy, which is almost as high as in the study by 
Rasmussen et al. (107). Our results comport with a study (46) where the sensitivity 
was 96% and specificity was 73% for malignant lesions in the lungs; it also comports 
with an FDG-PET study (109) and with a study that compared FDG-PET with 99mTc-
depreotide scintigraphy (72) in a small group of 29 patients. The later study showed a 
greater sensitivity, but the difference was not statistically significant. Therefore, we 
concluded that 99mTc-depreotide scintigraphy is a good diagnostic alternative for 
centres where PET is not available. 
 
We consider 99mTc-depreotide scintigraphy as a complementary method in patients 
with suspected lung carcinoma, applied after routine examinations. Based on the 
results of our Study I, the following strategy for use of 99m Tc-depreotide 
scintigraphy in the clinical work-up of patients with suspected lung cancer is 
suggested: If the radiological diagnosis is malignant, 99mTc-depreotide scintigraphy 
will not add valuable information. If the radiological diagnosis is indeterminate and 
pneumonia is excluded, the 99mTc-depreotide scintigraphy is of value both in 
malignant and in benign lesions. Because of the high negative predictive value of 
99mTc-depreotide scintigraphy, a negative result will rule out malignancy. This is 
valuable for avoiding unnecessary surgery. If the radiological diagnosis is benign, 
99mTc-depreotide scintigraphy will not add any new information. 
 
In our study more than one third of the pulmonary lesions were classified as 
indeterminate after CT examination. This is a great problem in clinical practice and is 
also reported by Rasmussen et al. (107), using high-resolution CT (HRCT). 
Rasmussen et al. (107) showed that there is no need for further investigations or 
follow-up examinations in patients with indeterminate findings on HRCT and 
negative results in 99mTc-depreotide scintigraphy. 
 
Even though the study from our group of 99mTc-depreotide uptake in the regional 
lymph nodes in patients with lung cancer is not included in this thesis, the results are 
still important. Absence of 9mTc-depreotide uptake on scintigraphic imaging can 
exclude regional lymph node involvement with a high degree of probability and may 
be useful in clinical practice. 
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So, lung cancer could be imaged using SSTRS with 99mTc-depreotide, and this 
method, by definition, is based on expression of somatostatin receptors (SSTRs) in 
cancer tissue. Such an expression is a known phenomenon for small-cell lung cancer. 
The situation with NSCLC at the time we conducted this study was unclear. Despite 
NSCLC often producing positive results in imaging with 99mTc-depreotide (48), 
previous studies (110) have failed to detect the expression of SSTR in NSCLC, while 
more recently published studies demonstrate an expression (111–113). 
 
Our study showed with immunohistochemical methods that all 19 NSCLC tumours 
expressed SSTR2. A reason for the contradictory results could be the different 
analytic methods used by different authors. 
 
In our study, SSTR2 expression correlated significantly with tumour differentiation; 
the higher the expression of SSTR2, the higher the differentiation of the tumour. 
However, further studies should be conducted to establish the role of SSTR2 in 
determining staging and prognosis. This observation might be used for selection of 
patients for targeted therapy with cytostatic drugs or radio-emitting agents attached to 
somatostatin receptor analogues. 
 
Surprisingly, no significant correlation between 99mTc-depreotide uptake determined 
in vivo and SSTR2 expression determined in vitro was found. One explanation may 
be that SSTRs are also expressed in leukocytes and proliferating neuroendocrine cells 
around the tumour (114), or in infiltrating lymphocytes (115). Neither lymphocytes, 
leukocytes, nor proliferating neuroendocrine cells around the tumour were evaluated 
in this Study II. We consequently performed this evaluation in our later study on 
oesophageal carcinoma. Another explanation may be that 99mTc-depreotide is known 
to bind to SSTR subtypes 2, 3, and 5. In Study II we measured only SSTR2 
immunohistochemically, and even this point we kept in mind in planning our next 
study on oesophageal carcinoma. We found 99mTc-depreotide uptake in all tumours, 
and the uptake in tumours was often higher in G3 tumours compared with G1 
tumours, but with some variations, and this correlation were therefore not significant. 
A study in which semi-quantitative tumour-to-normal lung ratio uptake of 99mTc-
depreotide was compared with different histological types of NSCLC showed that the 
ratio was highest in SqCC, lower in Ac, and lowest in large-cell carcinoma, but no 
data about tumour grade were present (116). In our sample 15 tumours are Ac and 
only 3 are SqCC and 1 neuroendocrine tumour. This may influence the result both for 
99mTc-depreotide uptake and expression of SSTR2 receptors. 
 
Determination of proliferative activity with the monoclonal antibody MIB-1, which 
binds Ki-67, a nuclear antigen, has been demonstrated to provide prognostic 
information (84, 85). We did not find a significant correlation between MIB-1 and 
99mTc-depreotide uptake. But we did find a significant negative correlation, that is, the 
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higher the MIB-1 expression in vitro, the lower the differentiation grade of the 
tumour. We also found a significant negative correlation, that is, the higher the MIB-
1, the lower the SSTR2 expression. However, the clinical application of this result is 
not clear. 
 
The role of p53 is instrumental to the regulation of G1 to S phase transition of the cell 
cycle. There was no correlation (p > 0.05) between p53 and either tumour 
differentiation or 99mTc-depreotide uptake. As previously described, some studies 
found mutations of p53 in more aggressive tumours (77), but others have not found 
such a correlation (78, 83). Few studies have found a negative prognosis with mutated 
p53 (79, 80), while other studies have found a better prognosis (81, 82). One study 
has identified 40 different mutations of p53 (78). In our study, we measured only 
expression of non-mutant p53, which may explain the lack of correlation. Whether 
this depends on the type of p53 mutation or is due to factors other than p53 that 
influence prognosis, such as other genes regulating cell growth or environmental 
factors, is still unclear. 
 
The results of our studies, however, should be considered in a wider perspective, 
where PET/CT has an established position in diagnosis in patients with suspected 
lung cancer. Since the beginning of this century an FDG-PET/CT has been 
considered to have a major impact on the management of lung cancer patients. Its 
value has been demonstrated by many publications, meta-analyses, and 
European/American/Japanese recommendations. Nowadays it is unquestionable that 
PET combined with CT provides useful information regarding the diagnosis and 
staging of lung cancer and allows for the delivery of adaptive radiotherapy. In its 
more common uses, PET/CT has been shown to be cost effective. With the 
widespread use of new radiotracers, PET/CT will play an increasing role in the 
evaluation of response to treatment. 
 
During the past two years PET/CT availability in Europe and in Sweden, particularly, 
is changing, with new scanners installed in several centres. The somatostatin receptor 
scintigraphy with gamma-photon-emitting isotopes was initially meant for the 
diagnosis of primary lung cancer. Even if the sensitivity of SSTRS with 99mTc-
depreotide in the diagnosis of primary tumour is close to that of FDG-PET/CT (71, 
72), the latter has several advantages, of which the facility for staging is one. The 
initial cost-benefit of SSTRS is no longer of great value, as it has risen and is now of 
the same value as FDG-PET. 
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5.2 OESOPHAGEAL CANCER 
As with lung cancer, the specificity in diagnosing lesions in the oesophagus by means 
of non-invasive radiological methods is limited. Despite the high sensitivity in 
detecting oesophageal cancer with 18F -FDG-PET/CT (92), these methods lack 
specificity; an elevated 18F-FDG uptake could be seen in different non-malignant 
conditions, such as inflammation and Barrett’s oesophagus (46, 47, 71, 72, 93). 
 
As SSTRS is based on a mechanism other than FDG-uptake in malignancies, it was 
of interest to find out whether this method could be useful to differentiate between 
malignant and benign lesions in the oesophagus. As no one before us had used 
SSTRS in patients with suspected oesophageal cancer, it was first necessary to 
determine whether it was feasible. We had a hypothesis that it was feasible to image 
oesophageal cancer by means of somatostatin receptor scintigraphy with 99mTc-
depreotide. Our hypothesis was based on two facts: first, that the physiological 99mTc-
depreotide uptake in the thorax is low. Therefore, this could be a suitable area for 
tumour detection in most cases. Second, we hypothesized that oesophageal cancer has 
the same main histopathological types as lung cancer, such as Ac and SqCC. As 
scintigraphy with 99mTc-depreotide is useful for lung cancer detection, this second 
fact suggested that it could also be applied in oesophageal cancer. 
 
The results of Study III support this hypothesis, and imaging of oesophageal 
carcinoma by means of SSTRS with 99mTc-depreotide is feasible. The majority of 
tumours (16 of 21) displayed a significant uptake of the tracer, which could be clearly 
distinguished from that in the surrounding tissue. It was not unexpected that tumours 
under or near 10 mm in size were missed in the scintigraphic images. The detection 
limit of the conventional gamma camera due to poor spatial resolution is well known, 
and according to widespread consensus, scintigraphic methods are not suitable for 
screening purposes for any cancer types. Another observation is that even larger 
tumours in the distal part of the oesophagus, 4 of 13 in the present study, could be 
missed with this method. Uptake of 99mTc-depreotide in lung cancers located in the 
lowest part of the right low lobe (71), and even in oesophageal cancers located at the 
level of the diaphragm and lower in the abdomen, could be obscured because of the 
high physiological tracer uptake in the liver. 
 
Our sensitivity figure of 76% is only an approximate value, due to the small number 
of patients in this study. Still, this is somewhat lower than both the sensitivity for 
detecting lung cancers (46, 47, 71, 72) with the same tracer and that for detecting lung 
cancer with FDG-PET (71, 72). While 18F-FDG uptake reflects a metabolic activity of 
the lesion and is not specific to tumours (71, 72), over-expression of somatostatin 
receptors on tumour cells could give another valuable piece of information regarding 
tumour properties. 
 
 40 
As a control group, we used patients with Barrett’s oesophagus. Barrett’s oesophagus 
refers to an abnormal change (metaplasia) in the cells in the lower end of the 
oesophagus. It is thought to be caused by damage from chronic acid exposure, or 
reflux oesophagitis. This metaplasia confers an increased risk of adenocarcinoma. 
None of the 13 cancer-free Barrett’s oesophagus patients in this study showed an 
increased 99mTc-depreotide uptake. Meanwhile, only 3 of 5 patients with both cancer 
and Barrett’s oesophagus showed an increased 99mTc-depreotide uptake, leaving 2 
false negative results. The specificity of 100% for the applied method is high, but 
should be used with caution, as the number of patients was relatively low and the 
spectra of different benign conditions in the oesophagus were not fully represented in 
this pilot study. 
 
Our results in the detection of loco-regional lymph node metastases were 
unsatisfactory. Only 5 of 13 patients with metastases seen with EUS and confirmed 
by histological examination were clearly detected by 99mTc-depreotide scintigraphy. 
This was probably caused by the close location to the primary tumour, where a high 
depreotide uptake cannot be separated from the uptake in the metastatic lymph nodes. 
It was disappointing to note that very few of the local, metastatic lymph nodes could 
be detected by this method. Through this pilot observation it can be envisioned that 
this technology cannot add to the available methods, such as EUS, in determining the 
node status in oesophageal cancer during the diagnostic and therapeutic work-up.  
 
As this study is the first of its kind, we considered it important to explore whether the 
quantitative assessment was reliable between different investigators and over time. 
Both intraobserver and interobserver variability was very low, meaning that the 
applied calculations have good reliability. 
 
We applied a somatostatin receptor scintigraphy with 99mTc-depreotide in a 
previously non-explored cancer type where the optimal acquisition time was 
unknown. We used the same starting point for the imaging session as for the standard 
procedure in the detection of lung cancer, that is, 2 hours after injection (47). During 
the last decade there has been a trend of performing a double-phase registration in 
order to increase specificity. The double-phase registration is based on assumptions 
that the relative tracer uptake in benign lesions decreases with time, while uptake in 
malignant lesions remains high, or even increases with time (47, 117–120). This 
approach is now routine for parathyroid scintigraphy, and its use has also been 
suggested for scintimammography, tumour imaging with FDG-PET, and somatostatin 
receptor scintigraphy with 99mTc-depreotide in lung cancer patients (117–120). In 
order to optimize the imaging procedure from the very beginning, we performed 
double-phase registrations with imaging 2 and 4 hours after injection. Our results 
showed that in the majority of patients the absolute uptake decreased more rapidly in 
the background (i.e. the normal lung parenchyma compared to the malignant lesions 
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in the oesophagus), resulting in a higher relative uptake in cancer over time. As both 
the 2-hour and the 4-hour quantitative evaluations showed a statistically significant 
difference (p < 0.005) between 99mTc-depreotide uptake in malignant lesions and in 
lesions without cancer, the 4-hour imaging seems unnecessary, and thus could be 
omitted for practical reasons. 
 
Although future immunohistochemical studies would explore the density, 
distribution, and localization of somatostatin receptors in the SqCC and Acs, our data 
from Study III indicate that there is no major difference as reflected by the similarity 
in tracer accumulation between these two major tumour types. It is, however, of 
particular interest that in patients with Barrett’s oesophagus, no accumulation of 
tracer was observed either in those with or in those without dysplastic 
histomorphologic changes in the columnar epithelium. Since there is no 
corresponding pre-neoplastic condition, concerning the SqCC development, it can be 
hypothesized that the somatostatin receptor expression reaches far higher levels in 
infiltrative neoplastic growth than in the intraepithelial neoplastic disease states. If so, 
this observation may be potentially very important and offer unique clinical 
opportunities, for example, when PET/CT or somatostatin receptor scintigraphy with 
99mTc-depreotide technologies are applied. 
 
What could the future clinical application of our results be? Obviously, the method is 
not suitable for either screening or primary diagnosis, because of the method’s 
modest sensitivity. Could the uptake of 99mTc-depreotide be related to the prognosis 
of the oesophageal tumour? 
 
To answer this question we continued to explore in Study IV the tissue correlate to 
these in vivo observations by immunostaining of different somatostatin receptors in 
the respective tumours, and even in a precancerous condition. One important 
prerequisite for the potential implementation of the scintigraphy technology was the 
high level of intra- as well as interobserver agreement in the assessments. However, 
coming back to the originally formulated issues, the following statements seem to be 
justified: 
 
(1) SSTRs are expressed in oesophageal carcinoma, and more abundantly so in 
adenocancer specimens; (2) in vivo 99m Tc-depreotide uptake does not obviously 
correlate with the immunohistochemical detection of SSTR receptors of different 
subtypes in oesophageal carcinoma; (3) there is a questionable and clinically 
irrelevant correlation between the expression of these SSTRs and the grading of 
adenocancer; and (4) finally, we found that Barrett’s columnar epithelium contains 
these receptors, which can be displayed by 99m Tc-depreotide scintigraphy . 
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Based on the fact that the columnar epithelium of the stomach harbours substantial 
amounts of somatostatin cells (D-cells), it did not come as a surprise that we found 
SSTRs in adenocancers—in Barrett’s oesophagus but not in Sqcc. The variability 
among tumours and patients was unpredictable, and therefore, it can be assumed that 
our initial theory of introducing the idea that SSTRs are involved in key pathways for 
the development of these neoplastic processes cannot be supported by the present 
findings. The robustness and strength of these observations are reinforced by the fact 
that we carefully investigated many of the other subtypes of SSTR not previously 
determined for patients with NSCLC, such as SSTR2B, SSTR3, and SSTR5. 
Moreover, we were unable to find a clear correlation between the SSTR expression 
and the dysplasia scorings of the Barrett’s cases. The present observation that in 
adenocancers there might be an association between the grading of the tumour and 
the intensity of the somatostatin receptors to be stained, can either be a finding 
obtained by chance or be logically based on the reasonable assumption that the more 
differentiated the tumour is, the closer it resembles the ‘normal’ columnar epithelium, 
where the D-cells are quite abundant. 
 
The expression of SSTRs of different subtypes in the presently investigated patients 
with oesophageal carcinoma did not correlate with the 99mTc-depreotide uptake on the 
scintigraphic imaging. This is in accord with our previous study on patients with 
NSCLC. Attempts have been made to explain and understand why tumours with high 
uptake of labelled somatostatin receptor analogue 99mTc-depreotide in scintigraphic 
images do not regularly express SSTRs on immunohistochemical examination of 
relevant tissue specimens. Kwekkeboom (114) et al. and Machac et al. (115) have 
suggested that the 99mTc-depreotide uptake on scintigraphic images may be due to the 
presence of accompanying leucocytes or activated neuroendocrine cells around the 
tumour cells (114) or in the surrounding granulomatous tissue (115). We tried to 
clarify this option by examining thoroughly the blocks from every one of our patients 
concerning signs of inflammation and the content of inflammatory cells, stroma cells, 
and vessels. By doing that, we could not observe any deviation in a direction that 
could explain the lack of correlation between uptake and the SSTR density. What 
other explanations for these findings can be considered? Is it possible that 99mTc-
depreotide scintigraphy is more sensitive to detecting SSTRs than the corresponding 
immunohistochemical methods used? Does 99mTc-depreotide bind nonspecifically to 
other structures or receptors on the cell surface than those residing in the D-cells? Is 
expression of SSTRs a dynamic or stable process, and which of these is picked up by 
the scintigraphic technology? Many questions remain to be answered before this 
method could be implemented into clinical practice. 
 
We noted a tendency for poorly differentiated tumours to have higher 99mTc-
depreotide uptake and this could be caused by nonspecific binding to areas of the cell 
surface, which could be more common on tumour cells with poor differentiation 
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compared to high differentiation. This corresponds to our previous observations in 
NSCLC, where poorly differentiated tumours had a higher 99mTc-depreotide uptake. 
However, this tendency was not statistically significant, either. In order to explore 
corresponding relationships in more detail much larger study cohorts are required. 
Patients without cancer but with a precancerous condition were enrolled, since it 
would be of special value to have a tool that could aid in the early detection of those 
who will subsequently develop neoplasia. Although we found somewhat higher 
99mTc-depreotide uptake in patients with dysplasia compared to those without, the 
overlap was substantial. Even in the immunohistochemical analysis the tendency was 
there to show that those with dysplasia more often expressed SSTRs (16 of 17) 
compared to those without dysplasia (13 of 21). The clinical value of these findings 
has to be further explored and substantiated in larger patient samples and with 
longitudinal evaluation. 
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6 FUTURE ASPECTS 
 
This thesis is based on the use of a single-photon-emitting tracer, but the results 
should be applicable or even better with positron-emitting tracers. Use of PET/CT 
cameras combines a better spatial resolution of functional PET imaging with detailed 
anatomical information, leading to a higher sensitivity. A multitude of new PET 
analogues are applied, whereas [68Ga-DOTA0, Tyr3] octreotide (DOTATOC) (56), or 
[68Ga-DOTA0, Tyr3] octreotate DOTATATE (33) are likely to become the new 
standard for somatostatin receptor imaging with PET. This is because these analogues 
have a high affinity for the somatostatin receptor subtype 2, and because 68Ga is a 
generator product with a relatively simple labelling (63). Another somatostatin 
analogue used for PET is DOTANOC, which has been useful for neuroendocrine 
tumours. This analogue binds to somatostatin receptors 2, 3, and 5 (51, 52). This 
analogue is also coupled to 90Y or 177Lu, forming 90Y- or 177Lu-labelled DOTANOC, 
which is used for peptide receptor radionuclide therapy (PRRT). It seems desirable 
that peptide used in diagnostic imaging mimics the peptide used later for therapy. 
 
After the successful visualization of somatostatin receptor–positive tumours, a logical 
next step would be to use radiolabelled somatostatin analogues as a treatment of these 
patients. Such attempts were undertaken in patients with inoperable and or/metastatic 
neuroendocrine tumours. While the objective responses for chemotherapy with the 
median time to progression is reported to be less than 18 months, PRRT with 90Y-
octreotide (DOTATOC) or 177Lu-octreotate (DOTATATE) performs considerably 
better with a median time to progression of 30 and 40 months, respectively (63), and 
significantly improves quality of life (64). 
 
Are there any questions of clinical use that could be further explored with SSTRS? 
Among the patients with lung neoplasms, 25% are represented by neuroendocrine 
tumours, whereas 2% are represented by typical carcinoid and 0.2% by atypical 
carcinoid (121). About 25% of patients with lung carcinoid are asymptomatic, so that 
bronchial carcinoids are found incidentally. 
 
 When imaged with FDG-PET/CT, these types of malignancies cause diagnostic 
difficulties. The FDG uptake could be absent, reflecting low metabolism of bronchial 
carcinoids. Carcinoid in the abdomen, as a subtype of neuroendocrine tumour, is 
successfully imaged with SSTRS and consequently treated with radiolabelled SSTR 
analogues. Even though in each published study, concerning imaging with SSRTS of 
patients with lung cancer, there are only a few carcinoids included, the dedicated 
studies of carcinoid in the lung are missing and could be conducted in the near future. 
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Concerning patients with oesophageal lesions, a study of whether uptake of SSTR 
analogues on scintigraphy could predict the natural history of Barrett’s oesophagus 
and its malignization is obviously the next step in the direction of future research. 
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7 CONCLUSION 
 
Study I. 99mTc-depreotide uptake has a very high sensitivity for lung cancer. It also 
has an acceptable specificity when pneumonias are excluded. Negative scintigraphy 
strongly suggests a benign lesion. This method is very useful in establishing the 
benign nature of hamartomas. It can be recommended clinically in decision making 
with respect to surgery. 
 
Study II. There is an expression of SSTR in NSCLC. The degree of tumour 
differentiation correlates positively with SSTR2A concentration. No significant 
correlation between SSTR2 scintigraphy with 99mTc-depreotide, MIB-1, and p53 
expression, and tumour grade was found. We found a significant negative correlation 
between MIB-1 expression, SSTR2A expression, and tumour grade. No correlation 
was found between p53 and tumour grade, or 99mTc-depreotide uptake. 
 
Study III. Scintigraphic examination with 99mTc-depreotide is feasible for imaging 
oesophageal cancer, but the method is not suitable either for screening or primary 
diagnosis, because of the method’s modest sensitivity. Our first results showed high 
specificity, which should be used with caution, as the number of patients was 
relatively low. Acquisitions starting 2 hours after injection are optimal, and suffice for 
imaging. 
 
Study IV. The majority of patients with Ac do express a low amount of SSTRs, while 
those are absent in the majority of patients with Sqcc. There was no correlation either 
between the 99m Tc-depreotide uptake and the amount of SSTRs or between the 
amount of SSTRs and differentiation grade of the tumour. There is somewhat higher 
99mTc-depreotide uptake and expression of SSTRs in the immunohistochemical 
analysis in patients with Barrett’s oesophagus and dysplasia compared to those 
without dysplasia. 
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